

October 15, 2014



# Atara Biotherapeutics Announces Pricing of Its Initial Public Offering

BRISBANE, Calif., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of \$11.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "ATRA" on October 16, 2014. In addition, Atara has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Atara at the initial public offering price to cover over-allotments, if any. The offering is expected to close on October 21, 2014, subject to customary closing conditions.

Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as joint book-running managers for the proposed offering. Jefferies LLC is acting as co-manager.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on October 15, 2014.

The offering is being made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to these securities may be obtained, when available, from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, by facsimile at (212) 902-9316, or by email at [prospectus-ny@ny.email.gs.com](mailto:prospectus-ny@ny.email.gs.com), or from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by email at [prospectus@citi.com](mailto:prospectus@citi.com) or by phone at (800) 831-9146.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

## About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a drug development company focusing on innovative therapies for patients with debilitating diseases. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications.

CONTACT: Tina Gullotta  
[tgullotta@atarabio.com](mailto:tgullotta@atarabio.com)  
415-287-2427

Source: Atara Biotherapeutics